The Yin and Yang of High-Density Lipoprotein Cholesterol**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 51, Issue 6, 2008, Pages 643-644

  Genest, Jacques ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

APOPTOSIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; EDITORIAL; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN FUNCTION;

APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CHOLESTEROL, HDL; HUMANS;

EID: 38749148091     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.10.033     Document Type: Editorial

References (15)

1. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
2. Nofer J.R., and Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 15 (2005) 265-271
3. Devries-Seimon T., Li Y., Yao P.M., et al. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J Cell Biol 171 (2005) 61-73
4. Tso C., Martinic G., Fan W.H., Rogers C., Rye K.A., and Barter P.J. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 26 (2006) 1144-1149
5. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62 (1977) 707-714
6. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
7. Sirtori C.R., Calabresi L., Franceschini G., et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 103 (2001) 1949-1954
8. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996) 2917-2923
9. van der Steeg W.A., Holme I., Boekholdt S.M., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 51 (2008) 634-642
10. Barter P., Gotto A.M., LaRosa J.C., et al., Treating to New Targets investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
11. Nissen S.E., Tardif J.C., Nicholls S.J., et al., ILLUSTRATE investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
12. Bots M.L., Visseren F.L., Evans G.W., et al., RADIANCE 2 investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370 (2007) 153-160
13. Kalantar-Zadeh K., Kopple J.D., Kamranpour N., Fogelman A.M., and Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 72 (2007) 1146-1156
14. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., and Fogelman A.M. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2 (2006) 504-511
15. Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117 (2007) 746-756